ICIs, particularly PD-1/PD-L1 inhibitors, are effective in treating melanoma,[29] renal cell carcinoma,[30] and colorectal cancer.[31] Research evidence shows that PD-1/PD-L1 blockades have improved overall survival (OS) than docetaxel for NSCLC[32]. Here, CD274 is linked to melanoma.